Biomea Fusion BMEA
NASDAQ BMEA
$1.37 +0.01 (+0.74%)
At close: Aug 21, 2026 · 4:00 PM EDT

Biomea Fusion (BMEA) Preferred Stock Liabilities (2020 - 2021)

Biomea Fusion (BMEA) posted Preferred Stock Liabilities of $55.7 million for Q1 2021, little changed sequentially from $55.7 million in Q4 2020.

Biomea Fusion (BMEA) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends

Biomea Fusion has reported Preferred Stock Liabilities for 2 years, with the latest figure at $55.7 million in Q1 2021.

  • Quarterly Preferred Stock Liabilities changed N/A year-over-year to $55.7 million in Q1 2021, while the trailing twelve-month figure through Mar 2021 was $55.7 million (changed N/A YoY) and the FY2020 annual result came in at $55.7 million, changed N/A from the prior year.
  • Preferred Stock Liabilities was little changed at $55.7 million in Q1 2021 per BMEA's latest filing, from $55.7 million in the prior quarter.
  • Over five years, Preferred Stock Liabilities peaked at $55.7 million in Q4 2020 and troughed at $55.7 million in Q1 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn -
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn -
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn -
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn -
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn -
9 Royalty Pharma 27.27 Bn 26.43 Bn - -
10 Biomea Fusion 97.69 Mn 97.69 Mn - -

Historic Data

Download Data
DateValue
Mar 31, 2021 55.74 Mn
Dec 31, 2020 55.74 Mn